[go: up one dir, main page]

BRPI0605508A - métodos para estabilização de composições oftálmicas - Google Patents

métodos para estabilização de composições oftálmicas

Info

Publication number
BRPI0605508A
BRPI0605508A BRPI0605508-7A BRPI0605508A BRPI0605508A BR PI0605508 A BRPI0605508 A BR PI0605508A BR PI0605508 A BRPI0605508 A BR PI0605508A BR PI0605508 A BRPI0605508 A BR PI0605508A
Authority
BR
Brazil
Prior art keywords
stabilizing
methods
ophthalmic compositions
ophthalmic
stabilizing ophthalmic
Prior art date
Application number
BRPI0605508-7A
Other languages
English (en)
Inventor
Azaam Alli
Shivkumar Mahadevan
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0605508A publication Critical patent/BRPI0605508A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS PARA ESTABILIZAçãO DE COMPOSIçõES OFTáLMICAS". A presente invenção refere-se a um método que compreende estabilizar, durante a colocação na autoclave, um composto oftálmico instável à oxidação dissolvido em uma solução oftálmica pela incorporação de uma quantidade efetiva de estabilização de pelo menos um polímero rico em elétrons na referida solução oftálmica.
BRPI0605508-7A 2005-09-30 2006-09-29 métodos para estabilização de composições oftálmicas BRPI0605508A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/240,930 US20070077302A1 (en) 2005-09-30 2005-09-30 Methods for stabilizing ophthalmic compositions

Publications (1)

Publication Number Publication Date
BRPI0605508A true BRPI0605508A (pt) 2007-09-04

Family

ID=37561295

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0605508-7A BRPI0605508A (pt) 2005-09-30 2006-09-29 métodos para estabilização de composições oftálmicas

Country Status (11)

Country Link
US (1) US20070077302A1 (pt)
EP (1) EP1774961A3 (pt)
JP (1) JP2007099769A (pt)
KR (1) KR20070037402A (pt)
CN (1) CN1939277A (pt)
AR (1) AR056558A1 (pt)
AU (1) AU2006225171B2 (pt)
BR (1) BRPI0605508A (pt)
CA (1) CA2561694A1 (pt)
SG (1) SG131102A1 (pt)
TW (2) TWI435735B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013201367B2 (en) * 2006-03-31 2014-07-17 Johnson & Johnson Vision Care, Inc. Ocular allergy treatments
UA94938C2 (ru) * 2006-03-31 2011-06-25 ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
EA016221B1 (ru) * 2006-03-31 2012-03-30 ВИСТЭКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмические композиции и способ лечения аллергических заболеваний глаз
US20100226999A1 (en) * 2009-03-06 2010-09-09 Tracy Quevillon-Coleman Process for forming stabilized ophthalmic solutions
TWI412381B (zh) * 2009-03-23 2013-10-21 Far Eastern New Century Corp Contact lens cleaning and maintenance liquid
TW202332446A (zh) * 2016-08-23 2023-08-16 日商大塚製藥股份有限公司 保存效果或光穩定性經改善之眼科藥用組成物
CN112312791B (zh) * 2018-06-27 2023-05-26 鲍希与洛姆伯股份有限公司 包装溶液
CN112807275B (zh) * 2019-11-15 2022-05-20 湖北远大天天明制药有限公司 一种眼用组合物及其制备方法与应用
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2422904A1 (de) * 1974-05-11 1975-11-20 Hoechst Ag Niedermolekulares poly-n-vinyl-nmethyl-acetamid fuer die anwendung in arzneimittelzubereitungen
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
JPH0725750A (ja) * 1993-05-20 1995-01-27 Medproject Pharma Entwickl & Vertriebs Gmbh 眼科用ゲル
CA2263411A1 (en) * 1996-08-12 1998-02-19 Eyal S. Ron Composition for pharmaceutical applications
JPH10139666A (ja) * 1996-11-15 1998-05-26 Sawai Seiyaku Kk 液剤およびその製造方法
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
EP1098649B1 (en) * 1998-04-02 2004-06-16 Novartis AG Method for stabilizing pharmaceutical compositions by special use of an antioxidant
WO2000001384A1 (fr) * 1998-07-01 2000-01-13 Lead Chemical Co., Ltd. Preparation a base de ketotifene destinee a etre absorbee par voie percutanee
US6444710B1 (en) * 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
CA2450070C (en) * 2001-06-14 2010-03-02 Cook Incorporated Endovascular filter
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine

Also Published As

Publication number Publication date
EP1774961A3 (en) 2007-09-05
JP2007099769A (ja) 2007-04-19
AU2006225171A1 (en) 2007-04-19
CA2561694A1 (en) 2007-03-30
CN1939277A (zh) 2007-04-04
US20070077302A1 (en) 2007-04-05
AU2006225171B2 (en) 2012-04-26
TW201247243A (en) 2012-12-01
EP1774961A2 (en) 2007-04-18
AR056558A1 (es) 2007-10-10
TWI435735B (zh) 2014-05-01
TW200728247A (en) 2007-08-01
TWI427052B (zh) 2014-02-21
KR20070037402A (ko) 2007-04-04
SG131102A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
GT201000114A (es) "mezclas fungicidas"
BR112015001618A2 (pt) composições fungicidas
BRPI0922824A8 (pt) compostos n-oxipiperidinas espiro-heterocíclicas como pesticidas, seu processo de preparação, composição pesticida que as contém e método de combater e controlar pestes
BRPI0621446B8 (pt) composição farmacêutica para uso externo
BRPI0607018A2 (pt) combinações sinérgicas de compostos ativas fungicidas
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
UY28800A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos
BRPI0720991A8 (pt) Preparação da romidepsina
BR112013028474A2 (pt) extrator de tendão do quadríceps
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
BR112021023927A2 (pt) Composto, e, composição farmacêutica
AR064327A1 (es) Un metodo para preparar montelukast e intermediarios utilizados en el mismo
BR0116332A (pt) Processo para o aumento da estabilidade
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BRPI0608245A2 (pt) compostos; processo para a sua fabricação; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças que estejam associadas à modulação de receptores de sst subtipo 5 e uso dos compostos
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
BRPI0418474A (pt) solução aquosa parenteral estável
BRPI0605508A (pt) métodos para estabilização de composições oftálmicas
AR062217A1 (es) Derivados de 4- trimetilamonio-3- aminobutirato y 4- trimetilfosfonio-3-aminobutirato como inhibidores de la cpt
CL2004000804A1 (es) Procedimiento de preparacion en una sola etapa de n-(n'-glicilo substituida)-2-cianopirrolidina.
UY30187A1 (es) Nuevas modificaciones cristalinas y solvato
CO6531477A2 (es) Composición de diagnóstico que comprende cationes en plasma con un perfil de seguridad superior

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.